Bladder cancer Cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients undergoing initial or first transurethral resection of bladder tumour (TURBT) for suspected bladder cancer
Exclusion criteria
Exclusion criteria: 1. Radiological or clinical suspicion of muscle-invasive bladder cancer (cT2-T4) 2. Prior diagnosis of NMIBC or MIBC on prior resection 3. Patients who do not consent for ex vivo tissue research through Imperial College Healthcare Tissue Bank (ICHTB) 4. Patients enrolled in concurrent clinical trials requiring ex vivo tissue for research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The feasibility of using digital fluorescence confocal microscopy to identify the presence/absence of detrusor muscle in primary transurethral resection of bladder tumour (TURBT) specimens measured by a pathologist who will determine the accuracy at one timepoint | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Establish a standard operating procedure for scanning fresh bladder tissue from primary TURBTs using the Histolog FCM machine at one timepoint 2. Agreement of digital FCM with the pathology report for detrusor presence on a specimen at a patient level. Sensitivity, specificity, positive and negative predictive value of digital FCM for detection of detrusor muscle with traditional H&E histopathology as the reference standard, on a per-patient basis at one timepoint 2. Agreement between readers measured by: a) two individual histopathologists; and, by b) a histopathologist versus an operating urological surgeon (Cohen’s kappa coefficient) at one timepoint | — |
Countries
England, United Kingdom